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Background: There is controversial evidence on whether arteriovenous access (AVA) 
placement may protect renal function and hence should be considered in the timing of access 
placement. This study aimed to investigate the association between AVA placement and 
eGFR decline as compared to placement of a peritoneal dialysis catheter (PDC) at a similar 
time point. 
Method: We studied a cohort of 744 predialysis patients in Stockholm, Sweden, who 
underwent surgery for AVA or PDC between 2006 and 2012. Data on comorbidity, 
medication and laboratory measures was collected 100 days before and after surgery. Patients 
were followed until dialysis start, death or 100 days, whichever came first. The primary 
outcome was difference in eGFR decline after AVA surgery compared to PDC. Decline in 
eGFR was estimated through linear mixed models with random intercept and slope, before 
and after surgery.  
Results: There were 435 AVA and 309 PDC patients. The AVA patients had higher eGFR 
(8.1 vs 7.0 ml/min/1.73m2) and less rapid eGFR decline before surgery (-5.6 compared to -6.7 
ml/min/1.73m2/year for PDC). We found no difference in eGFR decline after surgery in AVA 
patients compared with PDC patients (AVA progressed -1.14 (-2.38; 0.10) 
ml/min/1.73m2/year faster after surgery compared to PDC).  
Conclusion:  There was no significant difference in eGFR decline after placement of an AVA 
compared to a PDC. Both forms of access were associated to reduced eGFR decline in our 







A central question in clinical nephrology is when to create dialysis access. Timely preparation 
of an arteriovenous access (AVA) improves patient survival and facilitates hemodialysis 
initiation.1 Planning of an AVA is part of the multidisciplinary predialysis care associated 
with improved clinical outcomes such as less acute dialysis, cardiovascular events and 
infections.2  The timing of the AVA placement is challenging, especially in the elderly patient 
where delayed access maturation can occur. Late AVA placement increases the risk of 
dialysis start with a central venous catheter (CVC), which is associated with both infections 
and inferior survival.3 On the other hand, if the AVA is created very early, there is a higher 
probability it will never be used.4 It has been proposed that AVA surgery should take place 
when eGFR decreases to 15-20 ml/min/1.73m2.5 According to guidelines a fistula should be 
placed at least 6 months before the anticipated start of dialysis.6 With time, the individual 
eGFR slope has gained increasing importance over the actual eGFR in the decision of when 
planning for AVA surgery.7  
During recent years it has also been discussed whether the placement of an AVA itself could 
be seen as an intervention which has a possibility to attenuate chronic kidney disease (CKD) 
progression.8 This has been supported by several studies suggesting that AVA placement is 
associated with reduced eGFR decline.9-11 The physiological reasons for these observations 
were suggested to be related to cardiovascular and microcirculatory changes.12,13 However, 
these previous studies had questionable control groups; one study did not have a control group 
at all and another used patients who received a CVC. 9,10  Although CVC- patients represent a 
different patient category with more acute illnesses, late referrals and less predialytic 





In this study we investigated whether the creation of an AVA is associated with slower eGFR 
progression in a contemporary cohort of nephrology-referred patients planned for 
hemodialysis and compared that to the eGFR decline of patients who received a peritoneal 
dialysis catheter (PDC).  We hypothesized that any specific vascular or hemodynamic 
alterations occurring after the access surgery would only be present among AVA patients, 
while both groups benefitted from the advantages of a multidisciplinary follow-up during the 
pre-dialysis period.  
 
MATERIALS AND METHODS 
Study population 
Data were obtained from the Swedish Renal Registry (SRR) and the Stockholm CREAtinine 
Measurements (SCREAM) database to identify residents of Stockholm followed by 
nephrology out-patient healthcare. These two cohorts have been described in more detail 
previously.16,17 In short, SCREAM is a healthcare utilization database of the Stockholm 
population with linkages to other healthcare sources and SRR is the national renal registry 
with information on out-patient renal care, start of dialysis and transplantation. In this study 
we included patients (≥18 years) who were not on dialysis, with a hospital code for dialysis 
access surgery between March 1, 2006 and September 30, 2012, (for definitions see 
Supplement). We excluded patients who started dialysis on the same day as the surgery as 
they were judged to be unplanned starts.  
Access surgery and study variables 
The first date of any primary surgery for a dialysis access within the time period was 




access surgery; CVC, PDC and AVA (either an arteriovenous fistula or graft). Any patient 
with a code for both CVC and PDC or CVC and AVA on the same date was placed in the 
CVC group since they were not regarded as planned starts. Information on diabetes and 
cardiovascular disease on or before the index date was obtained through linkage with 
hospitalization codes, primary and secondary health care records. Ongoing medication was 
ascertained by the National Registry for Dispensed drugs which mandatorily register all 
dispensed prescriptions in Swedish pharmacies.18 A prescription for an angiotensin converting 
enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), beta-blocker or erythropoiesis 
stimulating agents (ESA) with on-going dispensations before the index date was considered as 
being treated. The ICD and ATC codes we used to define comorbidity and medication can be 
found in the Supplement. Clinical variables (primary renal disease, body mass index, (BMI) 
and systolic blood pressure) were ascertained from the SRR. Furthermore, we extracted 
information from SCREAM on additional laboratory measures of interest (haemoglobin, 
potassium, albumin, proteinuria (both dipstick and urinary albumin/creatinine ratio), 
phosphate, and calcium) during the study period. 
Decline in glomerular filtration rate 
All serum creatinine values from both in-hospital and out-hospital care were standardized to 
isotope dilution mass spectrometry standards.  Glomerular filtration rate (eGFR) was 
estimated by the CKD-EPI equation, assuming everyone was white.19  We hypothesized that 
the eGFR trajectory immediately prior to surgery was most likely associated with the timing 
of access placement. Therefore, for our main analysis, we excluded measurements >100 days 
before the index date. The eGFR closest to the index date was recorded as the eGFR at 
surgery.  After the index date, patients were followed until start of dialysis, death or 100 days 





The study variables were compared between patients receiving an AVA or a PDC by non-
parametric statistics. Mean eGFR over time was visualized graphically using smoothing 
techniques (Figure S2). Our main outcome, eGFR decline (ml/min/1.73m2 per year), was 
estimated by linear mixed models with random intercept and slope before and after access 
surgery. To deal with a slightly skewed distribution of slopes in the PDC group, we studied 
the difference in progression rate after surgery in a quantile regression model with eGFR 
slope as the dependent variable, excluding those who first received a CVC. In the main 
analyses we applied an intention- to- treat approach categorizing the patients into the 
treatment group they first received. Values were missing in fewer than 10 individuals, except 
for systolic blood pressure (n=190, 25%), primary renal disease (n=189, 25%), body mass 
index (n=219, 29%) and albuminuria (n=132, 18%). Missing variables were handled through 
multiple imputation (chained equations, n=20). The imputation model included the treatment 
variables, confounders, the outcome and time of follow-up. In the final model we included 
variables a priori considered important for treatment decisions or outcomes, as well as those 
significantly associated (<0.25) with either treatment or outcome. Model 1 included eGFR 
slope before surgery and last eGFR prior to surgery. Model 2 additionally adjusted for age 
(<50, 50-65, 65-75, >75 years), sex, primary renal disease and BMI. Model 3 included the 
variables from Model 2 + beta blockers, erythropoiesis stimulating agents, plasma albumin 
and albuminuria. We also computed the odds ratios of a 30% slower decline in eGFR/year 
after surgery in a logistic regression model adjusting for the same variables as in the 
regression models. Finally, we performed a propensity-matched analysis investigating the 
slope difference before and after surgery. To determine the propensity score (restricted only to 
those with overlapping propensity scores) we used a logistic regression model with AVA as 




treatment with ACEi/ ARB as explanatory variables. The command p-score in Stata 12 was 
used to estimate the propensity scores in blocks, checking that the mean propensity scores 
were not different for AVA and PDC in each block. The coefficients associated with the 
variables used to create the propensity scores are presented in Table S1. The balancing 
properties were found to be satisfactory (Table S2, Figure S1) and we proceeded with the 
matching procedure using both kernel matching and radius matching (caliper 0.01). Standard 
errors and 95% confidence interval were obtained through bootstrapping. We performed 
several sensitivity analyses using different model specifications (full follow-up time, mixed 
effects models for the eGFR slope post-surgery, and expanding the variables for the 
propensity score model). We also restricted the analysis by excluding those with poor AVA 
maturation who received a CVC before dialysis initiation. All analyses were performed in 
Stata 15 (StataCorp).  
 
RESULTS 
We identified 435 non-dialysis patients with an AVA placement and 309 with a PDC as their 
first dialysis access surgery during the study period. 53 patients received a CVC. The AVA 
patients were slightly older (64.5 versus 62.6 years), and more often men (63.5% versus 
62.5%) (Table 1). Compared with PDC patients, those who received an AVA more often had 
cardiovascular disease and diabetes. At the time of surgery, AVA patients had a lower 
frequency of erythropoietin stimulating agents and angiotensin converting enzyme inhibitor/ 
angiotensin receptor blocker use. Laboratory values (plasma albumin, haemoglobin, 
phosphate, calcium and albuminuria) were similar in PDC as compared with AVA patients.  




comorbid diseases, more laboratory abnormalities and were more often men, than those who 
received an AVA.  
Decline in eGFR before and eGFR at surgery  
The eGFR at the time of surgery was higher in patients who received an AVA (8.1 [AVA] 
versus 7.0 [PDC] ml/min/1.73m2). AVA patients had a less rapid decline before surgery (-5.6 
[AVA] compared with -6.7 [PDC] ml/min/1.73m2/year). Patients who received a CVC had the 
highest decline in eGFR before surgery and lowest eGFR at the time of surgery (Table 1). 
The follow-up period before surgery was similar in AVA and PDC patients while the follow-
up after surgery was slightly longer in AVA patients (Table 1). The median number of eGFR 
measurements after surgery was 5 (interquartile range 4-8), while the median number of 
measurements before surgery was 6.5.  
Decline in eGFR after surgery 
Both AVA and PDC patients had slower decline in eGFR after surgery compared with before 
(median slope difference in eGFR decline 5.3 ml/min/1.73m2) (Figure 1). Only 166 (22%) 
patients had a more rapid decline in eGFR after access surgery, most of those receiving an 
AVA. The median unadjusted decline in eGFR after access surgery was somewhat slower in 
AVA patients (-1.61 ml/min/1.73m2 per year) compared with PDC patients (-2.17 
ml/min/1.73m2 per year) (Table 2). However, in the fully adjusted model the PDC patients 
progressed 0.26 ml/min/1.73m slower (95% confidence interval -0.88; 0.35, p=0.40) than the 
AVA patients. The secondary analyses investigating the probability of a 30% slower decline 
(Table S3) and difference in slope before and after surgery using propensity score matching 
(Table 3) did not demonstrate any significant difference in eGFR decline between the two 




Sub analyses and sensitivity analyses 
Stratifying the analysis on the eGFR at the time of surgery did not influence the direction or 
the magnitude of the results (Table S3). In those with the most preserved renal function 
(eGFR >15 ml/min/1.73m2) the progression rate was higher in AVA patients compared with 
PDC patients. However, the confidence intervals were wide due to the low number of 
individuals. Using other model specifications or other regression models did not change the 
results substantially (Table S3). In our main analysis the median time to dialysis start was 59 
days and 154 days for PDC and AVA patients respectively. The total number of patients who 
received an access, but never started dialysis during the entire follow-up (median follow-up 
0.5 years (IQR 0.15-1.5 years), was 250 (33.6%), AVA  170 (39%) and PD 80 (26%)). At the 
end of the follow-up the patients who had not started dialysis had a median eGFR of 
8.3ml/min/ 1.73m² (IQR 5.6-12.6) (AVA) and 9.8ml/min/ 1.73m² (IQR 6.4-31.3) (PD).  In 
those who never started dialysis, the decline in eGFR was slower after access surgery in those 
who received a PDC compared with AVA patients. 
 
DISCUSSION 
In this study of nephrologist-referred patients under pre-dialysis care, we found that the eGFR 
decline was faster before than after the placement of a dialysis access. There was, however, 
no difference in eGFR decline after access surgery between those who received an AVA 
compared to those who received a PDC, indicating the lack of a specific effect from AVA 
creation per se on the progression rate. Our results are consistent with previous studies in the 
sense that we also detected a slower decline in eGFR after access surgery.10 The absolute 
decline in progression rate both before and after AVA placement in our study was comparable 




CVC patients were older, had more metabolic complications, faster eGFR decline before and 
lower eGFR at access surgery.10 On the other hand, in contrast to earlier studies, we found 
that when comparing AVA to PDC placement, there was no significant difference in the 
progression rate between the two access-types.   
Several pathophysiological hypotheses have been proposed to explain the apparent reduction 
of eGFR progression after AVA creation. One is the recruitment of a functional renal reserve 
in previously under perfused kidneys.20 AVA creation is associated to changes in hormonal 
and hemodynamic parameters, stroke volume and vascular resistance,21 changes in cardiac 
performance,22  and possibly ischaemic preconditioning. 23 In addition, reduced arterial 
stiffness, blood pressure and increased left ventricle ejection fraction have also been 
suggested.12 The same group also found remote microcirculatory changes associated to AVA 
placement.13  
By including a different control group, we could investigate if patients receiving an AVA 
indeed would have a larger reduction of eGFR decline post-surgery compared to PDC 
patients, due to the abovementioned physiological mechanisms. In contrast to previous 
suggestions in the literature, the observed lack of a difference between the two groups in our 
study suggests that although physiological mechanisms may be present, they did not influence 
the clinical eGFR trajectory in our population. If the reduction in eGFR progression after 
access surgery is less likely to be explained by physiological factors attributed to AVA 
surgery, it opens up for other explanatory models. In support of our findings, Sumida et al. 
previously found the progression rate decline to be independent of AVA maturation status10 
and Korsheed et al. noted effects on blood pressure and ejection fraction already two weeks 
after surgery.10,12 Compliance to prescribed medication, exercise and adherence to a protein 
restricted diet may be enhanced by the multidisciplinary nephrology care at a predialysis 




contacts and closer monitoring, these measures altogether may also have been involved in 
reducing the progression rate in both AVA and PDC patients. Another likely or contributing 
explanation for the slower eGFR progression after surgery may have been the statistical effect 
known as “regression towards the mean;” the decision of access surgery often occurs after a 
period of faster progression, statistically more frequently followed by a period of slower 
decline.26 It could also be possible that the dialysis access is created at a certain “tipping 
point” when uremic symptoms become more disabling, resulting in lower dietary intake and 
reduced muscle mass. Any eGFR based on serum creatinine would then be more likely to 
overestimate renal function and result in a falsely slower eGFR decline.  
Our study has several strengths. One is the complete and prospective inclusion of all patients 
receiving a dialysis access in a region during a given time period, with no loss to follow-up. 
Furthermore, Sweden has a tax-financed healthcare system where access to healthcare in 
general and nephrology is virtually equal for different socio-economic groups.  The referral 
guidelines are applicable to the whole region and there are no private nephrology clinics or 
dialysis units that were excluded in our material which increases generalizability. Our 
prospective design with two comparable pre-dialytic groups, (PDC and AVA), reduces 
confounding from differences in symptoms, access to medication and pre-dialytic healthcare, 
factors that in addition to access surgery may influence progression rate. In addition, we were 
able to collect extensive information about comorbidity, drugs and laboratory parameters.  
Like all observational studies, our study also has weaknesses. The tradition in Sweden is to 
create the dialysis access and start dialysis late. Therefore, our patients´ average eGFR at 
access surgery was lower than previous studies and one could hypothesize that a longer 
follow-up would have made a difference in AVA compared to PDC patients more likely.17 
Nevertheless, the progression rate before and after access surgery was very similar to previous 




substantial difference compared to our main results. Furthermore, when we looked at our 
cohort after a maximum of almost three years, we noted that about 1/3 of the patients who 
received an access never started dialysis, despite our later access creation. In addition, 
sensitivity analysis did not reveal any significant difference in our results when we analysed 
our data “as treated” to account for a proper AVA maturation. Although we used eGFR from 
serum creatinine, any misclassification due to dietary factors and loss of muscle mass would 
be similar in the two types of accesses.  
In conclusion, access surgery in general is associated with a reduction of the eGFR decline in 
our population. However, as there was no significant difference in eGFR decline after surgery 
for an AVA compared to a PDC, our study does not support to the hypothesis of a specific 
physiological effect of AVA placement on the eGFR decline. Thus, the need for dialysis still 
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Table 1. Demographics by dialysis access surgery in a regional, representative cohort of 











Age (Years) 65 (52-73) 63 (50-74) 69 (50-78) 
Men 276 (63.5) 193 (62.5) 40 (75.5) 
eGFR at surgery 
ml/min/1.73m2 
8.1 (6.4-10.6) 7.0 (5.3-8.9) 5.6 (4.4-7.1) 
Follow-up time before (days) 81 (92-63) 82 (93-63) 79 (92.5-63.5) 
Follow-up time after (days) 82 (61-92) 68 (21.5-90) 5 (2-8) 
eGFR decline/year prior to 
surgery (ml/min/1.73m2 ) 
-5.6 (-10.0- -1.3 ) -6.7 (-11.7- -3.7) -11.2 (-16.9- -6.3 ) 
Comorbidity     
Cardiovascular Disease 176 (41) 108 (35) 23 (43) 
Diabetes 172 (40) 111 (36) 29 (55) 
Current medication:    
ESA use 249 (57) 219 (71) 26 (49) 
ACE/ARB 293 (67) 229 (74) 37 (70) 
Beta-blockers 301 (69) 214 (69) 36 (68) 
Laboratory data:    
Albumin (g/l) 34 (31-37) 34 (31-37) 30 (25- 34.5) 
Calcium (mmol/l) 2.26 (2.14- 2.4) 2.25 (2.07- 2.38) 2.23 (1.99- 2.35) 
Phosphate (mmol/l) 1.7 (1.4-2) 1.8 (1.5-2.2) 2.15 (1.6-2.6) 
Hemoglobin (g/l) 113 (103-123) 112 (101-121) 102 (90-113) 
Potassium (mmol/l) 4.6 (4.1-5.1) 4.6 (4.2-5) 4.6 (4.3-5.0) 
ACR (<3 mg/mmol) 17 (4.9) 11 (4.1) 1 (2.0) 
(3-30 mg/mmol) 68 (19.7) 37 (13.9) 5 (10.2) 
(>30 mg/mmol) 260 (75.4) 219 (82.0) 43 (87.8) 
Clinical information:    
Systolic Blood Pressure 
(mmHg) 
145 (131.8-163) 145 (130-160) 142 (124.5-157.5) 




All continuous values are expressed as median (IQR), categorical values as number (%).  
ACE/ARB (angiotensin enzyme converting enzyme inhibitors/angiotensin receptor blockers), 
ACR (urinary albumin/creatinine ratio), BMI (body mass index), ESA (erythropoetin 
stimulating agents), eGFR (estimated glomerular filtration rate in ml/min/1.73m2, estimated by 
the CKD-EPI equation). To convert Calcium in mmol/l to mg/dL, divide by 0.2495. To convert 
Phosphate mmol/l to mg/dL, multiply with 3.0974. To convert Hemoglobin in g/l to g/dL, 
divide by 10. To convert creatinine from micromol/l to mg/dL multiply by 0.0113. 
 
Table 2. Differences in estimated glomerular filtration rate decline in after surgery for AV-




Median absolute decline in 
eGFR after surgery 
-2.17 (-2.85; -1.75) -1.61 (-2.12; -0.79) 0.07  
Unadjusted Ref. 0.56 (-0.58; 0.47) 0.22 
Model 1* Ref. -0.05 (-2.18; 0.34) 0.84 
Model 2** Ref. -0.09 (-0.68; 0.51) 0.78 
Model 3# Ref. -0.26 (-0.88; 0.35) 0.40 
Values are given as the difference in median decline (eGFRCKD-EPI (ml/min/1.73m
2/year); 95% 
confidence interval) for those who received a PD-catheter compared with AV-fistula. A negative 
difference indicates faster decline compared to the reference. A positive difference indicates a 
slower decline compared to the reference. A confidence interval including 0.0 indicates no 
difference between the two groups.  
*Model 1: Adjusted for slope before surgery (cubic) and eGFR at surgery; **Model 2: Model 1+ 
age, sex, primary renal disease and body mass index; #Model 3: Model 2+ ESA treatment, beta 
blocker treatment, plasma albumin, and albuminuria 
AV (arteriovenous), CVD (cardiovascular), eGFR (estimated glomerular filtration rate), ESA 





Table 3. Difference in eGFR decline before and after access surgery in AVAs compared to PDC 




Difference in eGFR 
decline after surgery 





Kernel matching 435/305 -4.17 -0.64; -8.79 
Kernel matching model 2 268/212 -1.65 0.67; -1.65 
Radius matching (0.01) 421/305 -2.33 1.46; -8.45 
Radius matching (0.01) 
model2 
255/210 -0.43 1.83; -2.69 
*standard errors and confidence intervals estimated through bootstrapping (100 reps)AVA 








Figure 1. Estimated glomerular filtration rate before and after access surgery  
 
Figure 1 subheading: Values are presented as unadjusted median decline in estimated 
glomerular filtration rate (95% confidence interval). *denotes a statistical significant 
difference (p<0.01) compared with pre-access surgery slope. Arteriovenous access (AVA), 
Peritoneal dialysis catheter (PDC) 
 
 
 
